pramipexole has been researched along with trimethoprim in 3 studies
| Studies (pramipexole) | Trials (pramipexole) | Recent Studies (post-2010) (pramipexole) | Studies (trimethoprim) | Trials (trimethoprim) | Recent Studies (post-2010) (trimethoprim) |
|---|---|---|---|---|---|
| 1,103 | 219 | 517 | 6,989 | 845 | 894 |
| Protein | Taxonomy | pramipexole (IC50) | trimethoprim (IC50) |
|---|---|---|---|
| Chain A, Dihydrofolate reductase | Bacillus anthracis | 77200 | |
| Chain A, dihydrofolate reductase (DHFR) | Bacillus anthracis | 77200 | |
| Dihydrofolate reductase | Mycobacterium avium | 0.2588 | |
| Dihydrofolate reductase | Homo sapiens (human) | 1.8206 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 0.3493 | |
| Dihydrofolate reductase type 1 | Escherichia coli | 0.25 | |
| Dihydrofolate reductase | Neisseria gonorrhoeae | 0.45 | |
| Thymidylate synthase | Homo sapiens (human) | 3.405 | |
| Dihydrofolate reductase | Staphylococcus aureus | 0.0875 | |
| Thymidylate synthase | Escherichia coli K-12 | 3.405 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 0.6064 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum K1 | 0.01 | |
| Dihydrofolate reductase type 1 from Tn4003 | Staphylococcus aureus | 0.023 | |
| Dipeptidyl peptidase 4 | Rattus norvegicus (Norway rat) | 2.7 | |
| Dihydrofolate reductase | Pneumocystis carinii | 0.7061 | |
| Dihydrofolate reductase | Candida albicans | 0.1361 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 2.7 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.45 | |
| Metabotropic glutamate receptor 5 | Rattus norvegicus (Norway rat) | 2.73 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 2.8 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 3.2206 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium berghei ANKA | 0.12 | |
| Dihydrofolate reductase | Streptococcus pneumoniae TIGR4 | 0.0297 | |
| Dihydrofolate reductase | Lactococcus lactis subsp. lactis Il1403 | 0.45 | |
| Dihydrofolate reductase | Bacillus anthracis | 4.77 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 1.244 | |
| Dihydrofolate reductase | Pneumocystis jirovecii | 0.092 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for pramipexole and trimethoprim
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for pramipexole and trimethoprim
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |